Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2005-03-22
2005-03-22
Kemmerer, Elizabeth C. (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S085100, C514S002600, C514S012200, C530S300000, C530S350000, C530S399000
Reexamination Certificate
active
06869609
ABSTRACT:
The invention presents a preparation for continuous intravenous administration containing hepatocyte growth factor (HGF) as an active ingredient. The preparation for continuous administration of the invention is effective at a lower dose as compared with single or frequent bolus administration of HGF, and therefore side effects can be reduced.
REFERENCES:
patent: 5360790 (1994-11-01), Humes et al.
patent: 5654404 (1997-08-01), Roos et al.
patent: 5703048 (1997-12-01), Roos et al.
patent: 6133234 (2000-10-01), Bunting et al.
patent: 6436388 (2002-08-01), Kudo et al.
patent: 0462549 (1991-06-01), None
patent: 0 462 549 (1991-12-01), None
patent: WO-9712628 (1997-04-01), None
patent: A1-9712628 (1997-04-01), None
Yo et al. Actions of hepatocyte growth factor as a local modulator in the kidney: potential role in pathogenesis of renal disease Kidney Int. 53(1):50-58, 1998.*
Amaike et al. Preventive effect of hepatocyte growth factor on acute side effects of cyclosporin A in mice. Cytokine 8(5): 387-394, 1996.*
Hayashi, S. Effects of LTB4 receptor anatagonist on myonephropathic metabolic syndrome: an experimental study. Kurume Med J 47(1): 63-72, 2000.*
Ioannou et al. Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J. 78(924):599-606, 2002.*
Mizuno et al. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest. 101(9):1827-1834, 1998.*
Singri et al. Acute renal failure. J Am Med Assoc 289(6): 747-751, 2003.*
Tsuji et al. Involvement of calpain in myonephropathic metabolic syndrome (MNMS). Eur J Vasc Surg. 8(4):482-488, 1994.*
Yaekashiwa et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in i murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med. 156: 1937-1944, 1997.*
Yamasaki et al. Hepatocyte growth factor protects functional and histological disorders of HgCI(2)-induced acute renal failure mice. Nephron. 90(2):195-205, 2002.*
Matsumoto et al. Jikken Igaku 15(9): 1040-1047, 1997.*
Tsukasa Igawa et al.,Am. J. Physiol, vol. 265, No. 1, Pt.2, F61-F69 (1993).
Kouichi Kawaida et al., Proc. Natl. Acad. Sci. USA, vol. 91, pp. 4357-4361 (1994).
Sang Kil Ha-Kawa et al.; Jpn. Pharmacol. Ther.; 24:149-152; 1996.
Kudo Ikue
Nagano Tomokazu
Sekine Michitoshi
Yamazaki Naoki
Birch & Stewart Kolasch & Birch, LLP
Bunner Bridget E.
Kemmerer Elizabeth C.
Sumitomo Pharmaceuticals Co. Ltd.
LandOfFree
Method for treatment of renal failure and occlusive lesion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of renal failure and occlusive lesion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of renal failure and occlusive lesion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3396166